Health ProductsNotice to Hospitals

Paclitaxel for Injection, 300mg/50mL - Glass Vial Defects for 3 Lots - Notice to Hospitals

· Published by Health Canada · Official notice

Details

Alert type: Notice to Hospitals
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Introduction

This is duplicated text of a letter from Hospira Healthcare Corporation.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Details

Notice to Hospitals - Health Canada Endorsed Important Safety Information on Paclitaxel for Injection, 300mg/50mL

June 26, 2012

Dear Healthcare Professional,

Please distribute to relevant Departments (Surgery, Emergency Medicine, Pharmacy, Paediatrics, Geriatrics, Internal Medicine, Oncology, Nursing, Intensive Care and/or other Departments as required), and other involved professional staff and post this Notice in your institution.

Subject: Glass Vial Defects for 3 Lots of Paclitaxel for Injection, 300mg/50mL, (DIN: 02296624)

Hospira Healthcare Corporation, in consultation with Health Canada, would like to inform you that complaints were received from customers outside of Canada of visible vial defects for multiple products. The vial defects may manifest as particles embedded in the glass vial, as rust-like marks on the vial or as particles in the solution. The three lots of Paclitaxel identified below and distributed in Canada were manufactured using the same affected empty glass vial, however, no defects or complaints have been reported to date for these lots. Paclitaxel for Injection is a clear colorless to slightly yellow viscous solution and is indicated in the treatment of carcinoma of the ovary, breast or lung.

Affected lots of Paclitaxel:

  • Y076847AB: Expiry date: 2013/12/31
  • Y026843AB: Expiry date: 2013/10/31
  • Y046843AB: Expiry date: 2013/12/31
  • Visible vial defects have been reported internationally for glass vials used for multiple products, however, no vial defects associated with these three lots of Paclitaxel have been reported.
  • As with all parenteral drug products, Healthcare Professionals should visually inspect the vial for particles and not use if any are present. In this situation, the particles or rust-like marks on the vial are of an obvious nature.
  • As per the Canadian Product Monograph, an in-line filter with a microporous membrane not greater than 0.22 microns should be used during the administration of Paclitaxel.

There are three potential scenarios for this defect:

  • The particulate matter is completely embedded within the glass and there is no contact with the solution. No patient impact will be noted.
  • The particulate matter is embedded within the glass but comes in contact with the solution.  This may give rise to soluble iron within the solution; however, the amount of iron present in the solution would be minimal and may not have any patient impact.
  • The particulate matter is free floating within the solution. Injected particulate matter may acutely cause direct mechanical damage on entry to the body (e.g. local inflammation, phlebitis), sub-acute low level allergic response through mechanical disruption of tissue or immune response to the particles and/or chronic granuloma formation in the lungs, vascular occlusion and possible embolism. In this instance, there is a potential for the injection of particulate matter which may result in significant patient impact; however, use of an in- line filter in the administration of Paclitaxel is expected to trap the particle(s) and mitigate the risk for patients.

Hospira has not received any reports of adverse events associated with these lots of Paclitaxel from its customers. An investigation is ongoing to determine corrective and/or preventive actions. Hospira commits to continue monitoring all product defect reports (complaints and retains). Additionally, Hospira will not release further inventory from these 3 lots of Paclitaxel. A shortage situation is not anticipated.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious specific adverse reaction or other serious or unexpected adverse reactions in patients receiving Paclitaxel for Injection (300mg/50mL) should be reported to Hospira Healthcare Corporation or Health Canada at the following addresses:

Hospira Healthcare Corporation
Complaint & Safety Department
1111 Dr.-Frederik-Philips, Suite 600
Saint-Laurent (Québec) H4M 2X6
To report an Adverse Reaction, consumers and health professionals may call toll free :
Telephone: 1-866-488-6088 Option 6
Fax: 1-877-906-0208
ProductcomplaintsCA@hospira.com

To correct your mailing address or fax number, contact Hospira Healthcare Corporation.

To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Lead Directorate: Health and Product and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-954-0941

Sincerely,

original signed by

Rania Al-Ammar
Regional Director, Commercial Quality
Hospira Healthcare Corporation

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime